The 45 references in paper S. Avdeev N., С. Авдеев Н. (2015) “Значение фиксированных комбинаций длительно действующих антихолинергических препаратов и длительно действующих #b2-агонистов в терапии хронической обструктивной болезни легких // A role of fixed combinations of long-acting anticholinergics and long-acting #b2-agonists in therapy of chronic obstructive pulmonary disease” / spz:neicon:pulmonology:y:2015:i:1:p:93-100

1
GOLD. Global Strategy for the Diagnosis, Management and Prevention of COPD. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Updated 2014. Available fromhttp:// www.goldcopd.org
(check this in PDF content)
2
Decramer M., Janssens W., Miravitlles M. Chronic obstruc\n tive pulmonary disease. Lancet. 2012; 379: 1341–1351.
(check this in PDF content)
3
Hogg J.C., McDonough J.E., Suzuki M. Small airway obstruction in COPD: new insights based on micro\nCT imaging and MRI imaging. Chest. 2013; 143: 1436–1443.
(check this in PDF content)
4
Qaseem A., Wilt T.J., Weinberger S.E. et al. Diagnosis and management of stable chronic obstructive pulmonary dis\n ease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann. Intern. Med.2011; 155: 179–191.
(check this in PDF content)
5
NICE. Clinical Guideline 101. Chronic obstructive pul\n monary disease. Management of chronic obstructive pul\n monary disease in adults in primary and secondary care (partial update issued June 2010). National Institute for Health and Clinical Excellence. 2010. Available from http://www.nice.org.uk/nicemedia/live/13029/49397/49397. pdf(Last accessed: January 24, 2014).
(check this in PDF content)
6
O'Reilly J., Jones M.M., Parnham J. et al. Guideline Development G. Management of stable chronic obstructive pulmonary disease in primary and secondary care: summa\n ry of updated NICE guidance. Br. Med. J. 2010; 340: 3134.
(check this in PDF content)
7
Rodrigo G.J., Plaza V. Efficacy and safety of a fixed\ndose combination of indacaterol and Glycopyrronium (QVA149) for the treatment of COPD: a systematic review. Chest. 2014; 146: 309–317.
(check this in PDF content)
8
Ball D.I., Brittain R.T., Coleman R.A. et al. Salmeterol, a novel, long\nacting beta 2\nadrenoceptor agonist: character\n ization of pharmacological activity in vitro and in vivo. Br. J. Pharmacol. 1991; 104: 665–671.
(check this in PDF content)
9
Casarosa P., Bouyssou T., Germeyer S. et al. Preclinical evaluation of long\nacting muscarinic antagonists: compari\n son of tiotropium and investigational drugs.J. Pharmacol. Exp. Ther. 2009; 330: 660–668.
(check this in PDF content)
10
Borrill Z.L., Houghton C.M., Woodcock A.A. et al. Measuring bronchodilation in COPD clinical trials. Br. J. Clin. Pharmacol. 2005; 59: 379–384.
(check this in PDF content)
11
Renard D., Looby M., Kramer B. et al. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model\n based approaches.Respir. Res. 2011; 12: 54.
(check this in PDF content)
12
Rennard S., Bantje T., Centanni S. et al. A dose\nranging study of indacaterol in obstructive airways disease, with a tio\n tropium comparison.Respir. Med.2008; 102: 1033–1044.
(check this in PDF content)
13
Singh D., Magnussen H., Kirsten A. et al. A randomised, placebo\n and active\ncontrolled dose\nfinding study of acli\n dinium bromide administered twice a day in COPD patients.Pulm. Pharmacol. Ther. 2012; 25: 248–253.
(check this in PDF content)
14
Cazzola M., Page C.P., Calzetta L., Matera M.G. Phar\n macology and therapeutics of bronchodilators. Pharmacol. Rev. 2012; 64: 450–504.
(check this in PDF content)
15
Hanania N.A., Boota A., Kerwin E. et al. Efficacy and safe\n ty of nebulized formoterol as add\non therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6\nweek, randomized, placebo\ncontrolled, clinical trial. Drugs. 2009; 69: 1205–1216.
(check this in PDF content)
16
Tashkin D.P., Littner M., Andrews C.P. et al. Concomitant treatment with nebulized formoterol and tiotropium in sub\n jects with COPD: a placebo\ncontrolled trial. Respir. Med. 2008; 102: 479–487.
(check this in PDF content)
17
Tashkin D.P., Pearle J., Iezzoni D., Varghese S.T. Formo\n terol and tiotropium compared with tiotropium alone for treatment of COPD. COPD. 2009; 6: 17–25.
(check this in PDF content)
18
Terzano C., Petroianni A., Conti V. et al. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD.Respir. Med.2008; 102: 1701–1707.
(check this in PDF content)
19
Noord J.A., Aumann J.L., Janssens E. et al. Effects of tiotropium with and without formoterol on airflow obstruc\n tion and resting hyperinflation in patients with COPD. Chest.2006; 129: 509–517.
(check this in PDF content)
20
Mahler D., D'Urzo A., Peckitt C. et al. Combining once\n daily bronchodilators in COPD: indacaterol plus tiotropium versus tiotropium alone. Am. J. Respir. Crit. Care Med. 2011; 183: A1591.
(check this in PDF content)
21
Aaron S.D., Vandemheen K.L., Fergusson D. et al. Tiotropium in combination with placebo, salmeterol, or flu\n ticasone\nsalmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.Ann. Intern. Med. 2007; 146: 545–555.
(check this in PDF content)
22
Tashkin D.P., Donohue J.F., Mahler D.A. et al. Effects of arformoterol twice daily, tiotropium once daily, and their combination in patients with COPD. Respir. Med.2009; 103: 516–524.
(check this in PDF content)
23
Noord J.A., Aumann J.L., Janssens E. et al. Compar\n ison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD.Eur. Respir. J.2005; 26: 214–222.
(check this in PDF content)
24
Noord J.A., Aumann J.L., Janssens E. et al. Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms.Respir. Med. 2010; 104: 995–1004.
(check this in PDF content)
25
Vogelmeier C., Kardos P., Harari S. et al. Formoterol mono\n and combination therapy with tiotropium in patients with COPD: a 6\nmonth study. Respir. Med. 2008; 102: 1511–1520.
(check this in PDF content)
26
Noord J.A., Buhl R., Laforce C. et al. QVA149 demon\n strates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax. 2010; 65: 1086–1091.
(check this in PDF content)
27
Calverley P.M., Burge P.S., Spencer S. et al. Bronchodilator reversibility testing in chronic obstructive pulmonary dis\n ease. Thorax. 2003; 58: 659–564.
(check this in PDF content)
28
Cazzola M., Segreti A., Matera M.G. New developments in the combination treatment of COPD: focus on umeclidini\n um / vilanterol. Drug Des. Devel. Ther.2013; 7: 1201–1208.
(check this in PDF content)
29
Bateman E.D., Mahler D.A., Vogelmeier C.F. et al. Recent advances in COPD disease management with fixed\ndose long\nacting combination therapies. Exp. Rev. Respir. Med. 2014; 8: 357–379.
(check this in PDF content)
30
European Medicine Agency. Ultibro Breezhaler. Available from EMA: http://www.ema.europa.eu/ema/index.jsp?curl=/ pages/medicines/human/medicines/002679/human_med_00 1691.jsp (accessed October 15, 2014).
(check this in PDF content)
31
Health Canada. Available from Health Canada: http:// www.hc+sc.gc.ca/dhp+mps/alt_formats/pdf/prodpharma/ applic+demande/regist/reg_innov_dr+end.pdf (accessed Oc\n tober 15, 2014).
(check this in PDF content)
32
Dahl R., Chapman K.R., Rudolf M. et al. Safety and effi\n cacy of dual bronchodilation with QVA149 in COPD pati\n ents: the ENLIGHTEN study. Respir. Med.2013; 107: 1558–1567. Обзоры Авдеев С.Н. Значение фиксированных комбинаций длительно действующих антихолинергических препаратов в терапии ХОБЛ
(check this in PDF content)
33
Bateman E.D., Ferguson G.T., Barnes N. et al. Dual bron\n chodilation with QVA149 versus single bronchodilator ther\n apy: the SHINE study.Eur. Respir. J.2013; 42: 1484–1494.
(check this in PDF content)
34
Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopy\n rronium and tiotropium (SPARK): a randomised, double\n blind, parallel\ngroup study.Lancet Respir. Med.2013; 1: 199–209.
(check this in PDF content)
35
Banerji D., Fedele M.J., Chen H., Kim H.J. Dual bron\n chodilation with QVA149 reduces COPD exacerbations: results from the ignite program. Respirology. 2013; 18 (Suppl. 4): 1–81.
(check this in PDF content)
36
Vogelmeier C.F., Bateman E.D., Pallante J. et al. Efficacy and safety of once\ndaily QVA149 compared with twice\ndaily salmeterol\nfluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, dou\n ble\nblind, parallel\ngroup study.Lancet Respir. Med.2013; 1: 51–60.
(check this in PDF content)
37
Zhong N., Wang C., Zhou X. et al. Efficacy and safety of once\ndaily QVA149 compared with twice\ndaily salmeterol\n fluticasone combination (SFC) in patients with COPD: the LANTERN study. Eur. Respir. J.2014; 44 (Suppl. 58): P2815.
(check this in PDF content)
38
Beeh K.\nM., Korn S., Beier J. et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir. Med.2014; 108: 584–592.
(check this in PDF content)
39
Mahler D.A., Decramer M., D'Urzo A. et al. Dual bron\n chodilation with QVA149 reduces patient\nreported dysp\n noea in COPD: the BLAZE study. Eur. Respir. J. 2014; 43: 1599–1609.
(check this in PDF content)
40
Dahl R., Gallagher N., Green Y. et al. QVA149 provides a rapid onset of action which is sustained throughout treat\n ment in patients with COPD. Eur. Respir. J.2013; 42 (Suppl. 57): 3385.
(check this in PDF content)
41
Dahl R., Jadayel D., Alagappan V.K. et al. Efficacy and safety of QVA149 compared to the concurrent administra\n tion of its monocomponents indacaterol and glycopyrroni\n um: the BEACON study. Int. J.COPD. 2013; 8: 501–508.
(check this in PDF content)
42
Ferguson G., Barnes N., Mehta R. Cardio\n and cerebro\n vascular safety profile of QVA149 in patients with COPD: a pooled analysis [Abstract]. Am. J. Respir. Crit. Care Med. 2013; 187 (1): A1488.
(check this in PDF content)
43
Wedzicha J.A., Dahl R., Buhl R. et al. Pooled safety analy\n sis of the fixed–dose combination of indacaterol and gly\n copyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients.Respir. Med. 2014; 108: 1498–1507.
(check this in PDF content)
44
Pavkov R., Mueller S., Fiebich K. et al. Characteristics of a capsule based dry powder inhaler for the delivery of inda\n caterol.Curr. Med. Res. Opin.2010; 26: 2527–2533.
(check this in PDF content)
45
Restrepo R.D., Alvarez M.T., Wittnebel L.D. et al. Medication adherence issues in patients treated for COPD. Int. J. COPD. 2008; 3: 371–384. Поступила 13.03.15 УДК 616.246036.126085.217
(check this in PDF content)